Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Syndax Pharmaceuticals (SNDX) EPS (Basic) (2016 - 2020)

Syndax Pharmaceuticals has reported EPS (Basic) over the past 6 years, most recently at -$0.44 for Q4 2020.

  • Quarterly results put EPS (Basic) at -$0.44 for Q4 2020, changed 0.0% from a year ago — trailing twelve months through Sep 2021 was -$0.44 (up 76.6% YoY), and the annual figure for FY2025 was -$3.29, up 11.56%.
  • EPS (Basic) for Q4 2020 was -$0.44 at Syndax Pharmaceuticals, up from -$0.46 in the prior quarter.
  • Over the last five years, EPS (Basic) for SNDX hit a ceiling of $0.79 in Q1 2018 and a floor of -$2.85 in Q1 2016.
  • Median EPS (Basic) over the past 5 years was -$0.47 (2016), compared with a mean of -$0.53.
  • Biggest five-year swings in EPS (Basic): soared 257.45% in 2018 and later plummeted 167.09% in 2019.
  • Syndax Pharmaceuticals' EPS (Basic) stood at -$0.59 in 2016, then crashed by 35.59% to -$0.8 in 2017, then soared by 187.5% to $0.7 in 2018, then tumbled by 162.86% to -$0.44 in 2019, then changed by 0.0% to -$0.44 in 2020.
  • The last three reported values for EPS (Basic) were -$0.44 (Q4 2020), -$0.46 (Q3 2020), and -$0.42 (Q2 2020) per Business Quant data.